Virtual Conference
Pharma Conference 2022

Alejandro Núñez Nolasco

Catholic University of Cibao , Dominican Republic

Title: Production of SARS-CoV-2 specific IFN-?/IL-10 co-producing CD4 T cells from convalescent donors to treat covid-19: A hypothesis


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has alarmed people worldwide as an emerging coronavirus, which to date remains a major global public health challenge. Patients are being treated with different therapies; however, no evidence of a single therapy has been found to improve the clinical outcomes significantly; therefore, there is currently no single effective treatment against COVID-19. The research related to virus-specific T cell therapy has provided positive results when treating Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Therefore, when facing a new virus, it is necessary to continue innovating the therapeutic strategies that have worked to treat viral infections previously, adapting to the pathogenesis of this new disease, to treat patients infected with SARS-CoV-2 effectively and safely. This proposal presents the research idea of creating SARS-CoV-2 specific interferon-gamma (IFN-?) and interleukin-10 (IL- 10) co-producing CD4 T cells to determine the cytokine secretion and viability of their production for virus-specific T cell therapy.


Alejandro made his first hypothesis in medicine at the age of 21 and published his first peer-reviewed article at the age of 22. He is a medical student at the Catholic University of Cibao (UCATECI) in the Dominican Republic. He has experience in rotating undergraduate internships and his scientific article has reached more than 3,500 views. He has been invited as an author for several renowned journals.